Association Between Expression of Immune Response-Related Genes and Response to Nivolumab in Metastatic Non-Small Cell Lung Cancer

被引：0
|
作者：
Obuti Saito, A. [1 ]
Araujo, D. [2 ]
Sousa Filho, C. [1 ]
Sa, D. [1 ]
Walter, L. [3 ]
Silva, A. P. [3 ]
Berra, C. [4 ]
Germano, J. [5 ]
Pinto, C. [6 ]
Carraro, D. M. [4 ]
De Lima, V. C. [1 ]
机构：
[1] AC Camargo Canc Ctr, Med Oncol, Sao Paulo, Brazil
[2] Hosp Base, Sao Jose Do Rio Preto, Brazil
[3] AC Camargo Canc Ctr, Biobank, Sao Paulo, Brazil
[4] AC Camargo Canc Ctr, Int Res Ctr, Genom & Mol Biol Grp, Sao Paulo, Brazil
[5] AC Camargo Canc Ctr, Stat, Sao Paulo, Brazil
[6] AC Camargo Canc Ctr, Pathol, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Nivolumab; gene expression profile; non-small-cell lung carcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P33.19
引用
收藏
页码：S413 / S413
页数：1
相关论文
共 50 条
  • [21] Correlation Between Immune-Related Adverse Events and Efficacy in Non-Small Cell Lung Cancer Treated with Nivolumab
    Sato, K.
    Akamatsu, H.
    Eriko, M.
    Sakaki, S.
    Kanai, K.
    Hayata, A.
    Tokudome, N.
    Akamatsu, K.
    Koh, Y.
    Ueda, H.
    Nakanishi, M.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2428 - S2429
  • [22] The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer
    Tanvetyanon, Tawee
    Creelan, Benjamin C.
    Antonia, Scott J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 903 - 910
  • [23] Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers
    Saftescu, Sorin
    Negru, Erban
    Volovat, Simona
    Popovici, Dorel
    Chercota, Vlad
    Stanca, Simona
    Feier, Horea
    Malita, Daniel
    Dragomir, Radu
    Volovat, Constantin
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (06)
  • [24] Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
    Sato, Koichi
    Akamatsu, Hiroaki
    Murakami, Eriko
    Hayata, Atsushi
    Tokudome, Nahomi
    Akamatsu, Keiichiro
    Koh, Yasuhiro
    Ueda, Hiroki
    Nakanishi, Masanori
    Yamamoto, Nobuyuki
    ANNALS OF ONCOLOGY, 2017, 28 : 86 - 86
  • [25] Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
    Sato, Koichi
    Akamatsu, Hiroaki
    Murakami, Eriko
    Sasaki, Seigo
    Kanai, Kuninobu
    Hayata, Atsushi
    Tokudome, Nahomi
    Akamatsu, Keiichiro
    Koh, Yasuhiro
    Ueda, Hiroki
    Nakanishi, Masanori
    Yamamoto, Nobuyuki
    LUNG CANCER, 2018, 115 : 71 - 74
  • [26] Immune related adverse events (irAE) and disease response with nivolumab in pre-treated advanced non-small cell lung cancer (NSCLC)
    Connolly, E.
    Mallesara, G.
    Nordman, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Prognostic Immune Markers in Non-Small Cell Lung Cancer-Response
    Suzuki, Kei
    Adusumilli, Prasad S.
    CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7836 - 7836
  • [28] Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer
    Haruki Kobayashi
    Shota Omori
    Kazuhisa Nakashima
    Kazushige Wakuda
    Akira Ono
    Hirotsugu Kenmotsu
    Tateaki Naito
    Haruyasu Murakami
    Masahiro Endo
    Toshiaki Takahashi
    International Journal of Clinical Oncology, 2017, 22 : 690 - 697
  • [29] Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer
    Kobayashi, Haruki
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Toshiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (04) : 690 - 697
  • [30] Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
    Schmid, Sabine
    Diem, Stefan
    Li, Qiyu
    Krapf, Mirjam
    Flatz, Lukas
    Leschka, Sebastian
    Desbiolles, Lotus
    Klingbiel, Dirk
    Jochum, Wolfram
    Fruh, Martin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (12) : 1825 - 1832
12345